Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC
Expert Rev Anticancer Ther. 2024 Apr 17. doi: 10.1080/14737140.2024.2344648. Online ahead of print.ABSTRACTINTRODUCTION: The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors and combination therapies, necessitates a profound understanding of resistance mechanisms for effective treatment strategies. Recognizing two primary categories - on-target and off-target resistance - underscores the need for comprehensive assessment.AREAS COVERED: This review delves into the intricacies of resis...
Source: Expert Review of Anticancer Therapy - April 17, 2024 Category: Cancer & Oncology Authors: Maria Gemelli Adriana Albini Gianpiero Catalano Matteo Incarbone Maria Cannone Emanuela Balladore Riccardo Ricotta Giuseppe Pelosi Source Type: research

The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis
CONCLUSION: ICI therapy in HCC should not be restricted strictly to certain patients in age or sex categories, while HCC patients with higher ECOG PS may require closer medication or follow-up strategy during ICI therapy.PROSPERO REGISTRATION: CRD42024518407.PMID:38623811 | DOI:10.1080/14737140.2024.2341723 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 16, 2024 Category: Cancer & Oncology Authors: Cheng-Long Han Bao-Wen Tian Lun-Jie Yan Zi-Niu Ding Hui Liu Guo-Qiang Pan Xiao Zhang Xin-Chen Mao Si-Yu Tan Rui-Zhe Li Dong-Xu Wang Zhao-Ru Dong Yu-Chuan Yan Tao Li Source Type: research

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy
Expert Rev Anticancer Ther. 2024 Apr 16. doi: 10.1080/14737140.2024.2344650. Online ahead of print.NO ABSTRACTPMID:38626305 | DOI:10.1080/14737140.2024.2344650 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 16, 2024 Category: Cancer & Oncology Authors: James A Davis Mary McGann Jessica Marini Hamza Hashmi Source Type: research

Do treatment patterns differ in those with early-onset colorectal cancer?
CONCLUSION: EOCRC patients are given more adjuvant chemotherapy, without a corresponding improvement in outcomes, highlighting a potential for increased treatment-related harms, particularly in stage 2 disease. Clinicians should be mindful of these biases when treating young cancer patients and need to carefully consider treatment-related harms.PMID:38619285 | DOI:10.1080/14737140.2024.2341731 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 15, 2024 Category: Cancer & Oncology Authors: Oliver Waddell Yahsze Teo Nasya Thompson Andrew McCombie Tamara Glyn Frank Frizelle Source Type: research

A meta-analysis of UCA1 accuracy in the detection of bladder cancer
CONCLUSION: UCA1 could serve as a potential biomarker for BCa detection with good diagnostic performance. Besides, compared to UCA1 in blood, urine and tissue UCA1 exhibited higher diagnostic value. Further prospective clinical research is needed to corroborate the conclusion.PROSPERO REGISTRATION: CRD42023463210.PMID:38606888 | DOI:10.1080/14737140.2024.2342528 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Silei He Jiawen Xu Minlin Chen Jiajin Li Shiqian Li Jufeng Ye Source Type: research

Targeting GPRC5D in multiple myeloma
Expert Rev Anticancer Ther. 2024 Apr 16:1-10. doi: 10.1080/14737140.2024.2343114. Online ahead of print.ABSTRACTINTRODUCTION: The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, has greatly improved patients' outcomes. Despite these advancements, relapses still happen often, and patients can become resistant to the usual treatments. Newer treatments, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA), h...
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Shatha Elemian Samer Al Hadidi Source Type: research

Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
Expert Rev Anticancer Ther. 2024 Apr 15:1-11. doi: 10.1080/14737140.2024.2343338. Online ahead of print.ABSTRACTINTRODUCTION: Statins, in the role of anti-cancer agents, have been used in many types of cancers with results in some cases promising while, in others, disappointing.AREAS COVERED: The purpose of this review is to identify and highlight data from literature on the successes or failure of using statins as anti-cancer agents. We asked ourselves the following two questions:1. Could statins, which are taken mostly to reduce cardiovascular risk, guarantee a lower incidence or a better cancer disease prognosis, concer...
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Luca Filaferro Fabiana Zaccarelli Giovanni Francesco Niccolini Andrea Colizza Federica Zoccali Michele Grasso Massimo Fusconi Source Type: research

Targeting GPRC5D in multiple myeloma
Expert Rev Anticancer Ther. 2024 Apr 12. doi: 10.1080/14737140.2024.2343114. Online ahead of print.ABSTRACTINTRODUCTION: The prognosis of multiple myeloma (MM) continues to improve. Recent progress in therapies, using immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies, has greatly improved patients' outcomes. Despite these advancements, relapses still happen often, and patients can become resistant to the usual treatments. Newer treatments, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA), have r...
Source: Expert Review of Anticancer Therapy - April 12, 2024 Category: Cancer & Oncology Authors: Shatha Elemian Samer Al Hadidi Source Type: research

Current usage of Pembrolizumab in triple negative breast cancer (TNBC)
Expert Rev Anticancer Ther. 2024 Apr 9. doi: 10.1080/14737140.2024.2341729. Online ahead of print.ABSTRACTINTRODUCTION: The use of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 pathway has changed the landscape in the treatment of triple negative breast cancer (TNBC). The ICI pembrolizumab in combination with chemotherapy now forms a standard of care for the treatment of advanced PD-L1 positive TNBC and as part of neoadjuvant therapy for high-risk early-stage disease. Evidence in this space is rapidly advancing.AREAS COVERED: This review aims to highlight the evolving role of immunotherapy in TNBC management ...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Harriet O'Rourke Christopher Hart Richard H De Boer Source Type: research

Role of non-coding RNAs mediated pyroptosis on cancer therapy: a review
Expert Rev Anticancer Ther. 2024 Apr 12:1-13. doi: 10.1080/14737140.2024.2341737. Online ahead of print.ABSTRACTINTRODUCTION: Non-coding RNAs (ncRNAs), which are incapable of encoding proteins, are involved in the progression of numerous tumors by altering transcriptional and post-transcriptional processing. Recent studies have revealed prominent features of ncRNAs in pyroptosis, a type of non-apoptotic programmed cellular destruction linked to an inflammatory reaction. Drug resistance has arisen gradually as a result of anti-apoptotic proteins, therefore strategies based on pyroptotic cell death have attracted increasing ...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Dan Zhao Tangwei Wu Zheqiong Tan Jia Xu Zhongxin Lu Source Type: research

Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Expert Rev Anticancer Ther. 2024 Apr 10. doi: 10.1080/14737140.2024.2341734. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy, but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis.AREAS COVERED...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Hana Studentova Katerina Hola Bohuslav Melichar Martina Spisarova Source Type: research